Core Insights - Ascendis Pharma is experiencing strong commercial growth for its products, particularly YORVIPATH and SKYTROFA, with significant revenue increases reported for Q4 2025 and full-year 2025 [3][4][7]. Commercial Performance - YORVIPATH generated €187 million in Q4 2025, contributing to a total of €477 million for the full year [3][7]. - SKYTROFA reported Q4 revenue of €53 million and full-year revenue of €206 million, with a U.S. market share of approximately 7% [11]. - The company has prescribed YORVIPATH to over 5,300 patients in the U.S. through nearly 2,400 healthcare providers, indicating a substantial long-term opportunity as less than 5% of U.S. patients are currently on treatment [2][7]. Financial Outlook - Ascendis ended 2025 with €616 million in cash and expects to achieve around €500 million in operating cash flow in 2026, with a long-term goal of at least €5 billion in annual product revenue by 2030 [5][20]. - Total revenue for Q4 2025 was €248 million, with operating expenses of €214 million, resulting in an operating profit of €10 million [17]. Pipeline and Regulatory Updates - The U.S. NDA for TransCon CNP is under review with a PDUFA date set for February 28, 2026, and the company anticipates full enrollment in its trial for infants with achondroplasia by late 2026 [6][13]. - Management highlighted the potential of a once-weekly TransCon PTH candidate, which aims to match the efficacy of daily therapies while improving patient convenience [8][12]. Market Expansion and Strategy - Ascendis plans to launch YORVIPATH in 10 additional countries in 2026, building on its existing commercial presence in over 30 countries [1]. - The company is also working to expand the label for SKYTROFA and is conducting trials to evaluate its growth hormone in additional indications, which could represent a significant market opportunity [10][11].

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was EUR 248 million, with full-year 2025 revenue totaling EUR 720 million, reflecting strong growth [20][21] - Europat revenue for Q4 was EUR 187 million, up from EUR 140 million in Q3, with full-year revenue reaching EUR 477 million [20][21] - SKYTROFA generated EUR 53 million in Q4, contributing to a total of EUR 206 million for the full year [20][21] - Operating profit for Q4 2025 was EUR 10 million, with operating cash flow of EUR 73 million [21] Business Line Data and Key Metrics Changes - Europat's U.S. patient prescriptions exceeded 5,300 from nearly 2,400 healthcare providers, indicating strong demand [8] - SKYTROFA holds a market share of approximately 7% in the U.S. for growth hormone deficiency treatments [10] - The company is expanding the Europat label and working on additional doses and indications, including trials for patients under 18 [9][11] Market Data and Key Metrics Changes - The overall insurance approval rate for Europat in the U.S. is about 70%, with expectations for gradual improvement [8][35] - Europat is commercially available in over 30 countries, with full reimbursement in four European countries and two international markets [9] - The company anticipates full commercial launches in 10 additional countries in 2026 [9] Company Strategy and Development Direction - The company aims to achieve EUR 500 million in operating cash flow by 2026 and at least EUR 5 billion in annual product revenue by 2030 [7][17] - Ascendis Pharma is focused on expanding its pipeline of blockbuster products and enhancing its global commercial infrastructure [7][16] - The company plans to leverage partnerships to create additional value and accelerate product development [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Europat and SKYTROFA, citing strong clinical value propositions [35] - The company is optimistic about the upcoming approval of TransCon CNP and its potential impact on revenue [22][56] - Management highlighted the importance of patient awareness and advocacy in driving product uptake [48] Other Important Information - The company is advancing its clinical trials for TransCon CNP and SKYTROFA, with significant data supporting their efficacy [12][51] - Ascendis Pharma is committed to maintaining independence and profitability as it grows, focusing on long-term value creation [93] Q&A Session Summary Question: Confidence level heading into the TransCon CNP PDUFA - Management expressed high confidence in the approval of TransCon CNP, similar to previous product approvals [28] Question: Insurance approval rate for Europat - Management is satisfied with the current 70% approval rate and noted that reaching 100% is unlikely due to natural filtering in patient eligibility [32][35] Question: Europat pricing and net pricing trends - Management does not discuss net pricing but expects stable revenue growth based on prescription increases [42][43] Question: Usage of Europat among prescribers - There is broad uptake among prescribers, with some treating multiple patients, indicating growing confidence in the product [47] Question: Confidence in Europat growth outside the U.S. - Management noted that uptake varies by country, with different speeds of penetration based on local market conditions [60] Question: TransCon CNP launch expectations - Management anticipates a strong initial uptake for TransCon CNP, leveraging U.S. approval for international markets [56] Question: Strategy for commercializing TransCon CNP globally - The company has established infrastructure through Europat to support rapid global commercialization of TransCon CNP [70] Question: Contribution of products to EUR 5 billion target by 2030 - Management emphasized a diversified product portfolio across multiple indications and regions to achieve sustainable revenue growth [76]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was EUR 248 million, with full-year 2025 revenue totaling EUR 720 million, reflecting strong performance [22][23] - YORVIPATH revenue for Q4 was EUR 187 million, up from EUR 140 million in Q3, with full-year revenue reaching EUR 477 million [22] - SKYTROFA generated EUR 53 million in Q4, contributing to a total of EUR 206 million for the full year [22] - Operating profit for Q4 2025 was EUR 10 million, with operating cash flow of EUR 73 million [23] - The company ended 2025 with EUR 616 million in cash and cash equivalents, an increase from EUR 560 million at the end of 2024 [23] Business Line Data and Key Metrics Changes - YORVIPATH saw over 5,300 patients prescribed by nearly 2,400 unique healthcare providers in the U.S., indicating strong demand [8] - SKYTROFA maintained a market share of around 7% in the U.S. for pediatric growth hormone deficiency and adult growth hormone deficiency [11] - The company initiated a phase III basket trial for TransCon Growth Hormone in established growth hormone indications, expanding its market potential [12] Market Data and Key Metrics Changes - In the U.S., the insurance approval rate for YORVIPATH is approximately 70%, with expectations for gradual improvement [8][36] - YORVIPATH is commercially available in over 30 countries, with full reimbursement in four European countries and two international markets [9] - The company anticipates full commercial launches in 10 additional countries in 2026 [9] Company Strategy and Development Direction - The company aims to achieve operating cash flow of around EUR 500 million in 2026 and at least EUR 5 billion in annual product revenue by 2030, as part of its Vision 2030 strategy [7][19] - Ascendis Pharma is focused on expanding its pipeline of blockbuster product opportunities while strengthening its global commercial infrastructure [7][19] - The company plans to invest in label expansion for current products and develop new blockbuster opportunities in rare endocrine diseases [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential of YORVIPATH, citing a significant opportunity as less than 5% of U.S. patients are currently on treatment [8] - The company is optimistic about the upcoming approval of TransCon CNP and its potential impact on revenue [24][57] - Management highlighted the importance of partnerships and collaborations to create additional value and support the development of differentiated product opportunities [17] Other Important Information - TransCon Growth Hormone is now approved in the U.S. for both adult and pediatric growth hormone deficiency, with ongoing trials to expand its indications [5][12] - The company is advancing its once-weekly TransCon PTH candidate for hypoparathyroidism, with expectations for significant market impact [6][21] Q&A Session Summary Question: Confidence level heading into the TransCon CNP PDUFA - Management expressed high confidence in the approval of TransCon CNP, similar to previous assurances regarding TransCon PTH [30] Question: Insurance approval rate for YORVIPATH - Management is satisfied with the current 70% approval rate and noted that reaching 100% is unlikely due to natural filtering in patient eligibility [36][39] Question: YORVIPATH pricing and net pricing trends - Management refrained from discussing net pricing but indicated a focus on revenue growth as the product matures in the market [44][45] Question: Usage of YORVIPATH among prescribers - Management noted broad uptake among prescribers, with some treating multiple patients, and emphasized the importance of awareness among patients [50] Question: Update on the COACH Trial for achondroplasia - Management reported positive feedback from regulatory meetings regarding the trial data and readiness to initiate phase III trials [52][53] Question: TransCon CNP launch expectations - Management anticipates a strong initial uptake for TransCon CNP, leveraging existing approvals to facilitate entry into international markets [57] Question: Strategy for commercializing TransCon CNP globally - Management highlighted the established infrastructure from YORVIPATH as a foundation for rapid global commercialization of TransCon CNP [73]

Group 1 - The call is led by Scott Smith, CFO of Ascendis Pharma, along with other key executives including Jan Moller Mikkelsen and Aimee Shu [2] - The presentation includes forward-looking statements related to the development of TransCon CNP and TransCon Growth Hormone combination treatment, as well as pipeline candidates [3]

Ascendis Pharma Conference Call Summary Company Overview - **Company**: Ascendis Pharma (NasdaqGS:ASND) - **Event**: Phase 2 Coach Trial Topline Week 52 Data Call - **Date**: January 08, 2026 Key Points Industry and Company Focus - **Industry**: Biotechnology, specifically focusing on treatments for achondroplasia and other growth disorders - **Core Product**: TransCon CNP and TransCon Growth Hormone Combination treatment Core Findings from the Coach Trial - **Trial Objective**: To evaluate the efficacy and safety of TransCon CNP combined with TransCon Growth Hormone in children with achondroplasia - **Patient Cohort**: 21 patients enrolled, including treatment-naive and treatment-experienced children [18][19] - **Primary Endpoint**: Annualized growth velocity at week 52, showing significant improvements [19][22] Efficacy Results - **Growth Velocity**: - Treatment-naive cohort: 8.8 cm/year, an increase of 3.9 cm/year from baseline [22][23] - Treatment-experienced cohort: 8.42 cm/year, an increase of 3.28 cm/year from baseline [24] - **Height Z-scores**: - Treatment-naive cohort: Increased from 0.46 to 1.47 [23] - Treatment-experienced cohort: Increased to 2.15 [24] - **Comparison to Historical Data**: Efficacy significantly exceeds historical benchmarks for achondroplasia treatments [6][7] Safety Profile - **Adverse Events**: 85% of adverse events were grade 1 (mild) and unrelated to the study drugs [21] - **No Cases of Symptomatic Hypotension**: Safety profile consistent with individual agents [21][22] - **Bone Age**: Remained consistent with chronological age, indicating no adverse effects on bone development [22] Additional Benefits - **Body Proportionality**: Improvements in upper to lower body segment ratios, indicating healthier bone growth [25][26] - **Arm Span Growth**: Statistically significant increase in arm span, reaching the 84th percentile compared to natural history in achondroplasia [27] Future Directions - **Phase 3 Trial Preparation**: Ongoing analysis of data to finalize the design of the phase 3 trial, focusing on both linear growth and additional benefits [30][41] - **Regulatory Submission**: TransCon CNP is under priority review with a PDUFA date of February 28, 2026 [52][81] Market Positioning and Pricing - **Combination Therapy**: Expected to be positioned as a leading treatment option for achondroplasia, addressing both growth and comorbidities [57][58] - **Pricing Strategy**: Anticipated to reflect the combined cost of both therapies, with considerations for global market variations [82] Conclusion - Ascendis Pharma is optimistic about the potential of TransCon CNP and TransCon Growth Hormone combination therapy to set a new standard in the treatment of achondroplasia, with significant efficacy and a favorable safety profile. The company is preparing for a phase 3 trial and is confident in the upcoming regulatory approval of TransCon CNP.

Core Insights - Ascendis Pharma A/S is a biopharmaceutical company focused on developing treatments for unmet medical needs, with products like SKYTROFA for growth hormone deficiency (GHD) and ongoing development of other treatments [1] Price Target Trends - The consensus price target for Ascendis Pharma has increased from $221.33 to $254 over the past year, indicating growing optimism among analysts regarding the company's future prospects [2][6] - Despite a lower price target of $161 set by Bank of America Securities analyst Tazeen Ahmad, the overall sentiment remains positive [2] Product Developments - Significant product developments, such as the approval of SKYTROFA for adults with GHD and the Priority Review of TransCon CNP by the U.S. FDA, have likely contributed to the positive analyst sentiment [3][6] - Progress with TransCon Growth Hormone and other treatments is crucial in shaping analyst outlook [3] Market Expansion - Ascendis Pharma's expansion into new markets, including Japan for pediatric GHD, has positively influenced analyst sentiment [4] - The global uptake of YORVIPATH further emphasizes the company's market expansion strategy [4] Financial Performance - In Q2 2025, Ascendis Pharma reported significant revenues of €103 million from YORVIPATH and €50.7 million from SKYTROFA, which likely bolsters analyst confidence in the company's growth potential [5][6] - Successful funding rounds also contribute to the positive trend in price targets [5]

Summary of Ascendis Pharma (ASND) Conference Call Company and Industry Overview - **Company**: Ascendis Pharma - **Industry**: Biotechnology, specifically focusing on treatments for growth disorders such as achondroplasia Key Findings from the COAST Trial - The COAST trial is a Phase II study assessing the efficacy of a combination therapy involving TransCon CNP and TransCon Growth Hormone in children with achondroplasia aged 2 to 11 years [2][3] - The trial reported a significant increase in annualized growth velocity (AGV) for treatment-naive children, achieving 9.14 cm/year, which is an increase of 4.2 cm/year compared to baseline [19][20] - For children previously treated with TransCon CNP, the AGV was 8.25 cm/year, reflecting a 3.1 cm/year increase from baseline [21][22] Efficacy and Safety Data - The combination therapy demonstrated a 0.53 increase in height Z score for treatment-naive patients and a 0.44 increase for treatment-experienced patients after 26 weeks [20][22] - The safety profile of the combination therapy was comparable to that of the individual therapies, with no serious adverse events related to the study drug reported [17][18] - The combination therapy resulted in a linear growth improvement associated with better body proportionality, which is crucial for children with achondroplasia [24][25] Future Development Plans - Ascendis Pharma plans to initiate a Phase III trial by the end of 2025, which will include both treatment-naive and experienced children [26][30] - The company aims to expand its treatment options for growth disorders and explore over 20 potential indications for its therapies [27][84] Market Position and Strategy - Ascendis Pharma is positioned as a leader in the growth disorder treatment market, with a focus on developing unique treatment combinations that unlock new therapeutic potentials [27][84] - The company is considering co-formulating TransCon CNP and TransCon Growth Hormone into a single injection for improved patient compliance [45][103] Additional Insights - The trial results indicate a potential for achieving catch-up growth in children with achondroplasia, which could normalize their height relative to parental expectations [80] - The combination therapy is expected to provide significant benefits beyond linear growth, addressing broader health concerns associated with achondroplasia [81][96] Conclusion - Ascendis Pharma's recent trial results highlight a promising advancement in the treatment of achondroplasia, with significant improvements in growth velocity and safety. The company is poised to expand its market presence and explore additional indications for its therapies, reinforcing its commitment to addressing growth disorders effectively.

Financial Data and Key Metrics Changes - Ascendis Pharma reported a significant increase in first quarter revenue for Europath, reaching €44.7 million, up from €13.6 million in the previous quarter [28] - Total revenue for the first quarter was €101 million, which includes non-product revenue from collaboration partners [30] - R&D costs for the first quarter totaled €86.6 million, compared to €70.7 million in the same quarter of the previous year [30] - SG&A expenses increased to €101 million from €66.8 million year-over-year, primarily due to global commercial expansion [31] Business Line Data and Key Metrics Changes - Europath's first quarter global revenue grew to €45 million, reflecting strong U.S. demand and a growing patient base [13][28] - Skytrofa revenue for the quarter was €51.3 million, with stable pricing and market share, although impacted by seasonal dynamics [29][18] - The company expects Europath to significantly contribute to revenue in 2025, with ongoing growth in both U.S. and international markets [16][28] Market Data and Key Metrics Changes - As of March 31, Europath was prescribed by over 1,000 unique prescribers for more than 1,750 patients in the U.S. [11] - The company estimates over 400,000 patients globally and around 70,000 in the U.S. are living with chronic hypoparathyroidism, with a significant portion being candidates for treatment with Europath [17] - Skytrofa holds approximately 7% market share in the total growth hormone market in the U.S. and around 43% in the non-active growth hormone market [18] Company Strategy and Development Direction - Ascendis Pharma aims to be a leading biopharma company, focusing on the global launch of Europath and the development of TransCon CNP for growth disorders [10][12] - The company is committed to expanding its product portfolio and addressing unmet medical needs in endocrinology and rare diseases [25] - Ascendis Pharma plans to submit an MAA for TransCon CNP in the EU in Q3 2025, with ongoing clinical trials to support its growth strategy [23][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong launch performance of Europath and its potential to become a multi-billion euro product [17] - The company anticipates substantial revenue growth driven by the global launch of Europath and continued contributions from Skytrofa [32] - Management highlighted the importance of favorable reimbursement dynamics and ongoing patient adherence as key factors for future success [41][42] Other Important Information - Ascendis Pharma recognized a non-cash gain of €33.6 million from its share of profit loss of associates due to the Visa IPO [31] - The company ended the first quarter with cash and cash equivalents totaling €518 million, down from €560 million at the end of 2024 [32] Q&A Session Summary Question: Expectations for reimbursement of Yorvapath - Management estimates that 17% to 18% of patients prescribed Yorvapath will ultimately get reimbursed, with ongoing positive trends in payer policies [39][40] Question: Split between U.S. and ex-U.S. revenue for Yorvapath - Management indicated steady growth in ex-U.S. markets, with expectations for acceleration in the second half of the year as more countries achieve full reimbursement [48] Question: Status of negotiations with commercial payers - Conversations with payers have been positive, with multiple favorable policies in place, and the company expects to continue gaining traction [54] Question: Proportion of new prescriptions from NATPARA or PTH naive patients - The majority of new patients are coming from conventional therapy, with about 10% to 15% having been on some form of PTH previously [58][62] Question: Depth of prescribing for Yorvapath - Management noted that they cannot definitively categorize patients as well-controlled or uncontrolled, but they are focusing on those frequently seeing endocrinologists [66][70] Question: Feedback on the titration process for Yorvapath - Adherence rates are consistent with clinical trials, and dropout rates are under 1%, indicating strong patient retention [100][101] Question: Plans for clinical utility trials for milder patients - Management is evaluating the long-term benefits of treatment for society and considering how to demonstrate the economic value of Yorvapath [108]